Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis

Bimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab is more efficacious than secukinumab over 1 year in the treatment of psoriasis. Objective: Evaluate the safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis. The...

Descripción completa

Detalles Bibliográficos
Autores: Strober, B.|||0000-0002-8394-2057, Paul, C., Blauvelt, A., Thaçi, D., Puig Sanz, Lluís|||0000-0001-6083-0952, Lebwohl, M., White, K., Vanvoorden, V., Deherder, D., Gomez, N.N., Eyerich, K.
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:303439
Acceso en línea:https://ddd.uab.cat/record/303439
https://dx.doi.org/urn:doi:10.1016/j.jaad.2023.04.063
Access Level:acceso abierto
Palabra clave:Bimekizumab
Clinical trial
Efficacy
Open-label
Plaque psoriasis
Psoriasis
Safety
Secukinumab
id ES_8d4136b3d14636e98abc477cde77ffb3
oai_identifier_str oai:ddd.uab.cat:303439
network_acronym_str ES
network_name_str España
repository_id_str
spelling Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasisTwo-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trialStrober, B.|||0000-0002-8394-2057Paul, C.Blauvelt, A.Thaçi, D.Puig Sanz, Lluís|||0000-0001-6083-0952Lebwohl, M.White, K.Vanvoorden, V.Deherder, D.Gomez, N.N.Eyerich, K.BimekizumabClinical trialEfficacyOpen-labelPlaque psoriasisPsoriasisSafetySecukinumabBimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab is more efficacious than secukinumab over 1 year in the treatment of psoriasis. Objective: Evaluate the safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis. The BE RADIANT phase 3b randomized controlled trial consisted of a 48-week double-blinded period, where patients received bimekizumab (320 mg every 4 or 8 weeks) or secukinumab (300 mg weekly to Week 4, then every 4 weeks), and an open-label extension (OLE). From Week 48, all patients received bimekizumab in the OLE. At Week 48, more patients achieved complete skin clearance (PASI 100; modified non-responder imputation) with bimekizumab than secukinumab (74.8% vs 52.8%). PASI 100 responses were maintained to Week 96 in continuous bimekizumab patients (70.8%); patients who switched from secukinumab to bimekizumab had increased rates at Week 96 (76.6%). The most common adverse events were: nasopharyngitis, oral candidiasis, and urinary tract infection. Safety data were consistent with the known safety profile of bimekizumab. Limited racial diversity; overlap with the COVID-19 pandemic. High PASI 100 responses achieved with bimekizumab over 48 weeks were sustained through Week 96; secukinumab patients who switched to bimekizumab achieved similar responses by Week 96.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/303439https://dx.doi.org/urn:doi:10.1016/j.jaad.2023.04.063reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3034392026-06-06T12:50:31Z
dc.title.none.fl_str_mv Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis
Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
title Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis
spellingShingle Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis
Strober, B.|||0000-0002-8394-2057
Bimekizumab
Clinical trial
Efficacy
Open-label
Plaque psoriasis
Psoriasis
Safety
Secukinumab
title_short Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis
title_full Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis
title_fullStr Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis
title_full_unstemmed Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis
title_sort Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis
dc.creator.none.fl_str_mv Strober, B.|||0000-0002-8394-2057
Paul, C.
Blauvelt, A.
Thaçi, D.
Puig Sanz, Lluís|||0000-0001-6083-0952
Lebwohl, M.
White, K.
Vanvoorden, V.
Deherder, D.
Gomez, N.N.
Eyerich, K.
author Strober, B.|||0000-0002-8394-2057
author_facet Strober, B.|||0000-0002-8394-2057
Paul, C.
Blauvelt, A.
Thaçi, D.
Puig Sanz, Lluís|||0000-0001-6083-0952
Lebwohl, M.
White, K.
Vanvoorden, V.
Deherder, D.
Gomez, N.N.
Eyerich, K.
author_role author
author2 Paul, C.
Blauvelt, A.
Thaçi, D.
Puig Sanz, Lluís|||0000-0001-6083-0952
Lebwohl, M.
White, K.
Vanvoorden, V.
Deherder, D.
Gomez, N.N.
Eyerich, K.
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Bimekizumab
Clinical trial
Efficacy
Open-label
Plaque psoriasis
Psoriasis
Safety
Secukinumab
topic Bimekizumab
Clinical trial
Efficacy
Open-label
Plaque psoriasis
Psoriasis
Safety
Secukinumab
description Bimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab is more efficacious than secukinumab over 1 year in the treatment of psoriasis. Objective: Evaluate the safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis. The BE RADIANT phase 3b randomized controlled trial consisted of a 48-week double-blinded period, where patients received bimekizumab (320 mg every 4 or 8 weeks) or secukinumab (300 mg weekly to Week 4, then every 4 weeks), and an open-label extension (OLE). From Week 48, all patients received bimekizumab in the OLE. At Week 48, more patients achieved complete skin clearance (PASI 100; modified non-responder imputation) with bimekizumab than secukinumab (74.8% vs 52.8%). PASI 100 responses were maintained to Week 96 in continuous bimekizumab patients (70.8%); patients who switched from secukinumab to bimekizumab had increased rates at Week 96 (76.6%). The most common adverse events were: nasopharyngitis, oral candidiasis, and urinary tract infection. Safety data were consistent with the known safety profile of bimekizumab. Limited racial diversity; overlap with the COVID-19 pandemic. High PASI 100 responses achieved with bimekizumab over 48 weeks were sustained through Week 96; secukinumab patients who switched to bimekizumab achieved similar responses by Week 96.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/303439
https://dx.doi.org/urn:doi:10.1016/j.jaad.2023.04.063
url https://ddd.uab.cat/record/303439
https://dx.doi.org/urn:doi:10.1016/j.jaad.2023.04.063
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413030309134336
score 15,81155

Similares en LA Referencia